

Author Index Volume 16 (2014)

- Acosta, P., see Olivera, M.E. (3,4) 289–312
- Barros, C., see Olivera, M.E. (3,4) 289–312
- Borges, L.L., M.L. Garcia, D. Silveira and E.C. da Conceição,
Herbal medicines in Brazil: Legal rules (3,4) 277–281
- Caffaratti, M., see Olivera, M.E. (3,4) 289–312
- Carvalho Mastroianni, P., see Olivera, M.E. (3,4) 289–312
- Castello, S.R., see Cervantes, P.P. (3,4) 249–266
- Cervantes, P.P., G.B. King, R.S. Vázquez, S.R. Castello, C.L. López
and E.A.D. Moreno, The practice of pharmaceutical patents (3,4) 249–266
- Cook, T., Data Protection and Market Exclusivities for Pharmaceu-
ticals in the EU (1,2) 19– 43
- Cook, T., The influence of TRIPs on the non-patent protection of
pharmaceuticals (1,2) 5– 17
- Cristofolletti, R., see Storpirtis, S. (3,4) 225–248
- da Conceição, E.C., see Borges, L.L. (3,4) 277–281
- Elvio, G., see Mercedes, S. (3,4) 283–287
- Escobar, L., see García, J.L. (3,4) 339–348
- Fagiolino, P., see Olivera, M.E. (3,4) 289–312
- Fontana, C., see Olivera, M.E. (3,4) 289–312
- Formica, M.L., see Real, J.P. (3,4) 313–320
- Gai, M.N., see Storpirtis, S. (3,4) 225–248
- García, J.L., H.V. Mardones, L. Escobar and E.M. Vega, The med-
icines situation in Chile: A critical appraisal from the academy (3,4) 339–348
- Garcia, M.L., see Borges, L.L. (3,4) 277–281
- Gassner, U.M., Recent developments in the area of supplementary
protection certificates (1,2) 45– 72
- Giraudó, F.J. and Z.M. Hugo, Drug's information and publicity: A
challenge for the pharmaceutical legislation (3,4) 321–337
- Hugo, Z.M., see Giraudó, F.J. (3,4) 321–337

- King, G.B., see Cervantes, P.P. (3,4) 249–266
- López, C.L., see Cervantes, P.P. (3,4) 249–266
- Maidana, M., see Olivera, M.E. (3,4) 289–312
- Maldonado, C., see Olivera, M.E. (3,4) 289–312
- Mardones, H.V., see García, J.L. (3,4) 339–348
- Mariela, B., see Mercedes, S. (3,4) 283–287
- Martich, E., see Tobar, F. (3,4) 207–224
- Mercedes, S., B. Mariela and G. Elvio, Characteristics of judicialization of health in relation to drugs (3,4) 283–287
- Moreno, E.A.D., see Cervantes, P.P. (3,4) 249–266
- Niioka, H., Non-patent protection of pharmaceuticals in Japan (1,2) 125–166
- Olivera, M.E., S.A.N. Uema, C.B. Romañuk, M. Caffaratti, P. Carvalho Mastroianni, F. Rossi Varallo, M. Vazquez, P. Fagioli no, C. Maldonado, E.M. Vega, Z. Vera Galvan, M. Maidana, P. Acosta, R. Rivero, C. Barros and D. Fontana, Regulatory issues on pharmacovigilance in Latin American countries (3,4) 289–312
- Palma, S.D., see Real, J.P. (3,4) 313–320
- Ramos-Cormenzana, A., Iberoamerican pharmaceutical academies (3,4) 349–361
- Real, J.P., S.L.G. Vásquez, M.L. Formica and S.D. Palma, Challenges and opportunities related to health promotion in community pharmacies: Obstacles and professional perspectives (3,4) 313–320
- Rivero, R., see Olivera, M.E. (3,4) 289–312
- Romañuk, C.B., see Olivera, M.E. (3,4) 289–312
- Rossi Varallo, F., see Olivera, M.E. (3,4) 289–312
- Sanchez, A.C., The “priority review vouchers” for neglected pharmaceutical innovation and their impact on pharmaceutical patents (1,2) 167–172
- Sellés, A.J.N., Pharma R&D in Latin America (3,4) 267–275
- Silveira, D., see Borges, L.L. (3,4) 277–281
- Storpirtis, S., M.N. Gai and R. Cristofolletti, Generic and similar products in Latin American countries: Current aspects and perspectives on bioequivalence and biowaivers (3,4) 225–248
- Thomas, J.R., Non-patent protection of pharmaceuticals in the USA (1,2) 89–123
- Tobar, F. and E. Martich, Economic tools for ensuring access to medicines in Latin American countries (3,4) 207–224

- Uema, S.A.N., see Olivera, M.E. (3,4) 289–312
- Valverde, J.L., Latin American pharmaceutical overview (3,4) 179–206
- Vásquez, S.L.G., see Real, J.P. (3,4) 313–320
- Vazquez, M., see Olivera, M.E. (3,4) 289–312
- Vázquez, R.S., see Cervantes, P.P. (3,4) 249–266
- Vega, E.M., see García, J.L. (3,4) 339–348
- Vega, E.M., see Olivera, M.E. (3,4) 289–312
- Vera Galvan, Z., see Olivera, M.E. (3,4) 289–312
- Zbierska, K., Relations between SPC and data exclusivity (1,2) 73– 87